自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响*

doi:10.3969/j.issn.1672-5069.2024.05.016

摘要/Abstract

摘要： 目的研究自身免疫性肝炎(AIH)和原发性胆汁性胆管炎(PBC)患者血清胆汁酸(BAs)成分变化及其对治疗应答的影响。方法 2020年1月～2023年1月我院诊治的28例AIH患者和55例PBC患者,分别接受醋酸泼尼松或熊去氧胆酸胶囊治疗。采用液相色谱-质谱联用法(LC-MS/MS)检测血清BAs成分,包括游离胆酸(CA)、去氧胆酸(DCA)、鹅去氧胆酸(CDCA)、熊去氧胆酸(UDCA)和石胆酸(LCA),甘氨结合型BAs包括糖胆酸(GCA)、糖去氧胆酸(GDCA)、糖去氧胆酸(GCDCA)和糖去氧胆酸(GUDCA)和牛磺结合型BAs包括牛磺酸胆酸(TCA)、牛磺酸去氧胆酸(TDCA)、牛磺酸去氧胆酸(TCDCA)和牛磺酸石胆酸(TLCA)。结果在治疗6个月末,AIH患者获得应答20例(71.4%),PBC患者获得应答42例(76.4%);AIH应答组血清CA、CDCA、UDCA和LCA分别为(1.6±0.5)ng/ml、(2.6±0.4)ng/ml、(2.0±0.3)ng/ml和(0.7±0.4)ng/ml,均显著低于未应答组【分别为(2.4±0.7)ng/ml、(2.9±0.4)ng/ml、(2.4±1.0)ng/ml和(0.9±0.7)ng/ml,P<0.05】,血清GCA、GDCA、GCDCA和GUDCA水平分别为(1.3±0.5)ng/ml、(2.6±0.3)ng/ml、(2.9±0.3)ng/ml和(1.6±0.5)ng/ml,均显著低于未应答组【分别为(3.0±1.0)ng/ml、(3.2±0.6)ng/ml、(3.8±0.8)ng/ml和(2.6±1.2)ng/ml,P<0.05】,血清TCA、TDCA、TCDCA和TLCA水平分别为(0.5±0.1)ng/ml、(2.6±0.2)ng/ml、(2.5±0.3)ng/ml和(0.1±0.0)ng/ml,均显著低于未应答组【分别为(2.1±1.2)ng/ml、(3.3±0.6)ng/ml、(2.7±0.4)ng/ml和(0.4±0.1)ng/ml,P<0.05】;PBC应答组血清CA、CDCA、UDCA和LCA水平分别为(1.7±0.4)ng/ml、(2.7±0.4)ng/ml、(2.1±0.4)ng/ml和(0.8±0.4)ng/ml,均显著低于未应答组【分别为(2.3±0.9)ng/ml、(3.0±0.4)ng/ml、(2.5±0.7)ng/ml和(1.3±0.7)ng/ml,P<0.05】,血清GCA、GDCA、GCDCA和GUDCA水平分别为(1.4±0.7)ng/ml、(2.6±0.4)ng/ml、(3.0±0.5)ng/ml和(2.0±0.9)ng/ml,均显著低于未应答组【分别为(2.9±0.9)ng/ml、(3.2±0.5)ng/ml、(3.8±0.7)ng/ml和(3.0±1.1)ng/ml,P<0.05】,血清TCA、TDCA、TCDCA和TLCA水平分别为(0.5±0.2)ng/ml、(2.7±0.3)ng/ml、(2.5±0.4)ng/ml和(0.2±0.1)ng/ml,均显著低于未应答组【分别为(2.1±0.9)ng/ml、(3.2±0.5)ng/ml、(2.8±0.4)ng/ml和(0.5±0.2)ng/ml,P<0.05】。结论虽然PBC和AIH患者血清BAs水平有显著性差异,但血清Bas水平升高或在治疗过程中不下降者,可能影响对治疗的应答,其机制还有待于探讨。

关键词: 自身免疫性肝炎, 原发性胆汁性胆管炎, 胆汁酸, 治疗, 应答

Abstract: Objective The aim of this study was to explore bile acid (BA) composition changes and their impact of response to immunosuppressant or ursodeoxycholic acid (UCDA) therapy in patients with autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Methods 28 patients with AIH and 55 patients with PBC were encountered in our hospital between January 2020 and January 2023, and they received prednisone or UDCA therapy. Serum free BAs, including cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA) and lithocholic acid (LCA), lycine-binding BAs(G-BAs), including glycocholic acid (GCA), glycodeoxycholic acid (GDCA), glycodeoxycholic acid (GCDCA) and glycodeoxycholic acid (GUDCA), and taurocholate-binding bile acid (T-BAs), including taurine cholic acid (TCA), taurine deoxycholic acid (TDCA), taurine deoxycholic acid (TCDCA) and taurine lithocholic acid (TLCA) levels were detected by liquid chromatography tandem mass spectrometry. Results By end of six month treatment, complete response to therapy in patients with AIH was found in 20 cases (71.4%) and in patients with PBC was found in 42 cases (76.4%); serum CA, CDCA, UDCA and LCA levels in AIH responders were (1.6±0.5)ng/ml, (2.6±0.4)ng/ml, (2.0±0.3)ng/ml and (0.7±0.4)ng/ml, all significantly lower than [(2.4±0.7)ng/ml, (2.9±0.4)ng/ml, (2.4±1.0)ng/ml and (0.9±0.7)ng/ml, respectively, P<0.05], serum GCA, GDCA, GCDCA and GUDCA levels were (1.3±0.5)ng/ml, (2.6±0.3)ng/ml, (2.9±0.3)ng/ml and (1.6±0.5)ng/ml, all significantly lower than [(3.0±1.0)ng/ml, (3.2±0.6)ng/ml, (3.8±0.8)ng/ml and (2.6±1.2)ng/ml, respectively, P<0.05], and serum TCA, TDCA, TCDCA and TLCA levels were (0.5±0.1)ng/ml, (2.6±0.2)ng/ml, (2.5±0.3)ng/ml and (0.1±0.0)ng/ml, all significantly lower than [(2.1±1.2)ng/ml, (3.3±0.6)ng/ml, (2.7±0.4)ng/ml and (0.4±0.1)ng/ml, respectively, P<0.05] in non-responders; serum CA, CDCA, UDCA and LCA levels in PBC responders were(1.7±0.4)ng/ml, (2.7±0.4)ng/ml, (2.1±0.4)ng/ml and (0.8±0.4)ng/ml, all significantly lower than [(2.3±0.9)ng/ml, (3.0±0.4)ng/ml, (2.5±0.7)ng/ml and (1.3±0.7)ng/ml, respectively, P<0.05], serum GCA, GDCA, GCDCA and GUDCA levels were (1.4±0.7)ng/ml, (2.6±0.4)ng/ml, (3.0±0.5)ng/ml and (2.0±0.9)ng/ml, all significantly lower than [(2.9±0.9)ng/ml, (3.2±0.5)ng/ml, (3.8±0.7)ng/ml and (3.0±1.1)ng/ml, respectively, P<0.05], and serum TCA, TDCA, TCDCA and TLCA levels were (0.5±0.2)ng/ml, (2.7±0.3)ng/ml, (2.5±0.4)ng/ml and (0.2±0.1)ng/ml, all significantly lower than [(2.1±0.9)ng/ml, (3.2±0.5)ng/ml, (2.8±0.4)ng/ml and (0.5±0.2)ng/ml, respectively, P<0.05] in non-responders. Conclusion There are significant differences in serum bile acid levels between patients with PBC and with AIH, and serum BAs changes might be involved in pathogenesis of autoimmune liver diseases, and have some influence on outcomes of the diseases.

Key words: Autoimmune hepatitis, Primary biliary cholangitis, Bile acids, Ursodeoxycholic acid, Immunosuppressant, Therapy, Response

高怡, 沈小雪, 夏素芹, 张洁, 朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(5): 709-712.

Gao Yi, Shen Xiaoxue, Xia Suqin, et al. Bile acid composition and their impact of response to immunosuppressant or UCDA therapy in patients with autoimmune hepatitis and primary biliary cholangitis[J]. Journal of Practical Hepatology, 2024, 27(5): 709-712.

参考文献

[1] Wang R, Tang R, Li B, et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol, 2021, 18(1):4-17.
[2] Neshat SY, Quiroz VM, Wang Y, et al. Liverdisease: Induction, progression, immunological mechanisms, and therapeutic interventions. Int J Mol Sci, 2021, 22(13):6777.
[3] 崔娜娜, 王绮夏. 《2019年美国肝病学会实践指引和指南:成人和儿童自身免疫性肝炎的诊断与治疗》摘译. 临床肝胆病杂志, 2020, 36(4):758-763.
[4] Yang Y, He X, Rojas M, et al. Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis. Front Immunol, 2023, 14:1184252.
[5] Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol, 2022, 19(7):432-450.
[6] Mayo MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis? Hepatology, 2022, 76(2):518-531.
[7] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021年). 临床肝胆病杂志, 2022, 38(1):42-49.
[8] 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021年). 临床肝胆病杂志, 2022, 38(1):35-41.
[9] Sheps JA, Wang R, Wang J, et al. The protective role of hydrophilic tetrahydroxylated bile acids (THBA). Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(7):158925.
[10] McGlone ER, Bloom SR. Bile acids and the metabolic syndrome. Ann Clin Biochem, 2019, 56(3):326-337.
[11] Fiorucci S, Distrutti E, Carino A, et al. Bile acids and their receptors in metabolic disorders. Prog Lipid Res, 2021, 82:101094.
[12] Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol, 2023, 21(8):2076-2087.
[13] Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol, 2021, 27(1):1-21.
[14] Giannini EG, Pieri G, Labanca S, et al. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma.Dig Liver Dis, 2022, 54(9):1215-1221.
[15] Li J, Zhu X, Zhang M, et al.Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism. J Hepatol, 2021, 75(2):400-413.
[16] Su X, Gao Y, Yang R. Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity. Front Immunol, 2023, 14:1127743.
[17] Zhang J, Lyu A, Wang C. The molecular insights of bile acid homeostasis in host diseases. Life Sci, 2023, 330:121919.
[18] Bhattacharya A, Taylor RE, Guo GL. In vivo mouse models to study bile acid synthesis and signaling. Hepatobiliary Pancreat Dis Int, 2023, 22(5):466-473.
[19] Honda A, Miyazaki T, Iwamoto J, et al.Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J Lipid Res, 2020, 61(1):54-69.
[20] Lai Q, Ma Y, Bai J, et al.Mechanisms for bile acids CDCA- and DCA-stimulated hepatic spexin expression. Cells, 2022, 11(14):2159.

自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*

Bile acid composition and their impact of response to immunosuppressant or UCDA therapy in patients with autoimmune hepatitis and primary biliary cholangitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[3]	中国医药生物技术协会慢病管理分会肝病学组. 双环醇防治肝脏炎性损伤多学科专家共识[J]. 实用肝脏病杂志, 2024, 27(5): 659-668.
[4]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[5]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[6]	黎防, 杨宏飞, 张青. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(5): 685-688.
[7]	刘雅光, 胡连智, 董一侠, 刘洋. 抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 689-692.
[8]	莫伟斌, 张清友, 黄晓涵, 欧阳婉爱. 达诺瑞韦联合拉维达韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 693-696.
[9]	蒋叶舟, 花霞, 陈国飞, 朱青蓝, 蔡明月. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 713-716.
[10]	朱家瑞, 葛绍锋, 叶桂云, 黄远茂. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 717-720.
[11]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[12]	任艳, 孔明, 徐曼曼, 白丽, 陈煜. 瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 725-728.
[13]	王秀娟, 朱贺, 张茹梦, 常文绘, 刘玉玉. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者不同减量方法的效果研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 729-732.
[14]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[15]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.